GROWTH HORMONE AXIS RESEARCH / MATRIX
Three Peptides, Two Mechanisms, One Loose Category
How a GHRH-analogue-plus-GHRP stack, a mitochondrial signaling peptide, and the reference GHRH fragment differ in mechanism, evidence maturity, and what each is actually studied for.
The short version
This page lines up CJC-1295/Ipamorelin, MOTS-c, and sermorelin on the dimensions that matter most when reading growth-hormone-axis peptide research: what receptor or pathway each one actually engages, how much clinical evidence exists, and the single most important caution for each. The honest headline is that these three don't all belong to the same mechanism, even though they're often discussed together. Sermorelin and CJC-1295/Ipamorelin both target the pituitary's GH-release switches — one directly, one through two receptors at once. MOTS-c works entirely inside cells, on energy metabolism, and has no human interventional trial evidence at all. Reading them side by side is useful precisely because it shows where the category holds together and where it doesn't. None of this is medical advice, and no dose is recommended anywhere on this page.
The comparison matrix
| Dimension | CJC-1295 / Ipamorelin | MOTS-c | Sermorelin |
|---|---|---|---|
| Primary mechanism | Dual pituitary receptor activation: GHRH-R (CJC-1295) + GHS-R1a (ipamorelin) [5] | Intracellular AMPK activation + direct CK2 binding; mitochondrial-nuclear signaling [6][10] | Single pituitary receptor activation: GHRH-R [11] |
| Human clinical evidence | Single-agent data only; no trial of the fixed combination [3][4] | Observational human biomarker studies only; no interventional human trial [7] | Decades of published human trials, incl. pediatric and older-adult RCTs [15][16][17] |
| Most-studied population | Healthy adult volunteers (single-agent PK studies) [3] | Mice; one human hemodialysis cohort [6][7] | GH-deficient children; healthy older adults [15][17] |
| Regulatory status | Neither compound FDA-approved; sold as research chemicals | Not FDA-approved; sold as research chemical | Previously FDA-approved (discontinued brand, pediatric use); now compounded |
| Key caution | Fixed blend never tested in a controlled trial; mismatched component half-lives [3][4] | No human efficacy or dosing data exist at all [7][8] | Anti-aging/wellness use not evidence-justified per a widely cited editorial [13] |
Mechanism
The three peptides split cleanly into two mechanistic families. Sermorelin and the CJC-1295 half of the CJC-1295/Ipamorelin pairing are both GHRH analogues: they bind the GHRH receptor on pituitary somatotrophs and drive GH synthesis and release through the same cAMP pathway the body's own GHRH uses [11]. Ipamorelin adds a second, independent switch — the ghrelin receptor, GHS-R1a — which signals through calcium rather than cAMP; cell studies show activating both receptors together roughly doubles the cAMP signal compared with GHRH-receptor activation alone [5]. MOTS-c shares none of this. It is not a pituitary-receptor peptide at all — it works inside cells, inhibiting the folate cycle to activate AMPK and directly binding casein kinase 2, with tissue-specific effects on muscle and fat [6][10]. Grouping MOTS-c with the other two reflects research-community habit, not mechanistic overlap.
Evidence base
This is where the three separate most sharply. Sermorelin has the deepest evidence base by far: published trials in GH-deficient children, healthy young men, and healthy older adults spanning three decades [15][16][17], plus a recent comprehensive review of GHRH biology [11]. CJC-1295/Ipamorelin sits in the middle — each half has been studied on its own (CJC-1295's pharmacokinetics in healthy adults [3], the DAC chemistry in rats [4], receptor synergy in transfected cells [5]), and a class-level secretagogue safety review exists [2], but the fixed combination itself has never been tested in a controlled human trial. MOTS-c has the thinnest human evidence of the three: its data are almost entirely mouse studies, with the exception of one prospective human cohort that measured naturally circulating MOTS-c levels rather than testing it as an intervention [6][7][9].
Most-studied population and application
Sermorelin's trial record centers on two very different populations: prepubertal children with confirmed growth hormone deficiency, where it accelerated height velocity [15], and healthy older adults, where it (or a closely related GHRH analogue) reversed age-related GH/IGF-1 decline [17] and, in one related-analogue trial, improved cognition and reduced body fat [12]. CJC-1295/Ipamorelin's component data come mostly from healthy adult volunteers in single-agent pharmacokinetic studies [3][4]. MOTS-c's population is almost entirely rodent — young, aged, high-fat-diet, and immobilized mice [6][9] — with one notable exception: a multicenter cohort of chronic hemodialysis patients, where circulating MOTS-c tracked mortality and cardiovascular risk [7].
Regulatory status
Sermorelin previously held FDA approval under a now-discontinued brand for a specific pediatric indication; it was withdrawn from the market for commercial reasons in 2008, not for a safety or efficacy failure, and remains available today through compounding pharmacies. CJC-1295 and ipamorelin have never held FDA approval for any human use and are sold only as research chemicals. MOTS-c likewise has no FDA approval and no history of one — it has never advanced past preclinical and observational human research.
Key caution
For CJC-1295/Ipamorelin, the defining caution is that the fixed combination has never been tested as such — everything about how the two components behave together is inferred from separate single-agent data and cell-level synergy work, not measured directly [3][4][5]. For MOTS-c, the caution is more basic: no human efficacy trial exists at all, so questions about what it does in a person, at what dose, and how safely, remain open [7][8]. For sermorelin, the caution is about scope creep: the trial evidence strongly supports its original, narrow pediatric use and looks reasonably solid in short-term older-adult studies, but a widely cited editorial concluded that using GH secretagogues broadly to prevent or treat aging in healthy adults is "not yet ready for prime time" [13].